TY - JOUR
T1 - Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity
AU - De Jong, Trynke R.
AU - Pattij, Tommy
AU - Veening, Jan G.
AU - Dederen, P. Jos W.C.
AU - Waldinger, Marcel D.
AU - Cools, Alexander R.
AU - Olivier, Berend
PY - 2005/2/10
Y1 - 2005/2/10
N2 - The role of 5-HT (5-hydroxytryptamine, 5-HT)1A receptor activation in the sexual side-effects, in particular delayed ejaculation, of selective serotonin reuptake inhibitors (SSRIs) was studied. Male Wistar rats were treated for 15 days with vehicle, the SSRI citalopram (10 mg/kg/day p.o.), the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1- piperazinyl] ethyl]-N-(2-pyridinyl) cyclohexane carboxamide 3HCL (WAY 100635, 0.1 mg/kg/ day s.c.), or both drugs combined. Sexual behavior was assessed weekly. One h after the last sexual behavior test, rat brains were processed for Fos-immunohistochemistry. Acute and chronic citalopram mildly inhibited ejaculation, which was strongly augmented by co-administration of WAY 100635. WAY 100635 alone did not alter sexual behavior. Brain sites associated with ejaculation showed reduced Fos-immunoreactivity in rats treated with both citalopram and WAY 100635. Citalopram reduced Fos-immunoreactivity in the arcuate hypothalamic nucleus, an area that might link serotonergic neurotransmission to ejaculation.
AB - The role of 5-HT (5-hydroxytryptamine, 5-HT)1A receptor activation in the sexual side-effects, in particular delayed ejaculation, of selective serotonin reuptake inhibitors (SSRIs) was studied. Male Wistar rats were treated for 15 days with vehicle, the SSRI citalopram (10 mg/kg/day p.o.), the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1- piperazinyl] ethyl]-N-(2-pyridinyl) cyclohexane carboxamide 3HCL (WAY 100635, 0.1 mg/kg/ day s.c.), or both drugs combined. Sexual behavior was assessed weekly. One h after the last sexual behavior test, rat brains were processed for Fos-immunohistochemistry. Acute and chronic citalopram mildly inhibited ejaculation, which was strongly augmented by co-administration of WAY 100635. WAY 100635 alone did not alter sexual behavior. Brain sites associated with ejaculation showed reduced Fos-immunoreactivity in rats treated with both citalopram and WAY 100635. Citalopram reduced Fos-immunoreactivity in the arcuate hypothalamic nucleus, an area that might link serotonergic neurotransmission to ejaculation.
KW - 5-HT
KW - Antidepressant
KW - Ejaculation
KW - Selective serotonin reuptake inhibitor
KW - c-fos
UR - http://www.scopus.com/inward/record.url?scp=13844254489&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejphar.2004.12.024
DO - https://doi.org/10.1016/j.ejphar.2004.12.024
M3 - Article
C2 - 15713429
SN - 0014-2999
VL - 509
SP - 49
EP - 59
JO - European journal of pharmacology
JF - European journal of pharmacology
IS - 1
ER -